Lajos (Lou) Balogh is the Scientific Advisor and Owner of AA Nanomedicine and Nanotechnology, providing scientific guidance, feasibility assessment, and technology due diligence in Nanomedicine, Nanobiotechnology, and Nanotechnology for investors, private enterprises and government agencies since 2000. He is also the Editor-in-Chief of the “Nanomedicine: Nanotechnology, Biology and Medicine” journal (Elsevier). Dr. Balogh is a former Co-Director of the NanoBiotechnology Center and Director of Nanotechnology Research in the Department of Radiation Medicine (Roswell Park Cancer Institute), and served as faculty at the University at Buffalo SUNY, the University of Michigan, Ann Arbor, UMass Lowell, and at the Kossuth Lajos University, Hungary.
He has broad interdisciplinary experience in nanotechnology, chemistry, bioengineering, drug delivery, and cancer research. His research expertise involves general nanomedicine, targeted drug delivery, multifunctional contrast agents, and therapeutic materials; dendrimers and hybrid nanodevices. Dr. Balogh co-invented nanocomposites, photomechanical therapy and nanobrachytherapy; solved a number of synthetic, characterization, and purification problems for drugs, dendrimers, particles, and polymers. Dr. Balogh participates in the development of nanotechnology nomenclature, terminology, and standards as member of the US TC229 Technical Advisory Group to ISO on Nanotechnology. He received his PhD from Kossuth L. University, Hungary and is a member of a number of national and international expert committees. Lou has over 150 scientific publications, 1 book and six book chapters, 80 invited lectures, and 12 patents in chemistry, chemical and biomedical engineering, nanotechnology and Nanomedicine.
To learn more go to: http://www.linkedin.com/in/lajosbalogh